Comparison of Customized Allogenic Versus Autogenous Bone Block Graft for Alveolar Ridge Augmentation

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorMedical University of Graz

About this trial

The aim of this study is to determine whether jawbone augmentations using allogeneic and autogenous bone blocks lead to comparable three-dimensional clinical and radiological outcomes.

In addition, the study seeks to investigate whether there are differences regarding safety, biocompatibility, complications, and PROMs.

Furthermore, it aims to clarify whether differences exist between the two groups with respect to implant condition (one year after implantation and during annual follow-ups for up to five years).

Eligibility criteria

Qualifiers

1-4 missing teeth that need to be replaced with dental implants

Bone ridge width insufficient for dental implant placement; <5 mm of width as measured in a cone beam computed tomography at the ideal prosthetic position

Medically healthy with no known allergies to antibiotics

Non-smoker or light smoker (< 10) or previous smoker who had quit for 5 years or more

Disqualifiers

All contraindications against implant treatment or augmentative procedures (e.g., advanced systemic diseases, corticosteroid medication, immunodeficiency, pregnancy, intention to become pregnant, breastfeeding, lack of safe contraception)

Treatments or diseases that may have an effect on bone turnover or the bone itself or non-mineralized tissue metabolism (e.g., bisphosphonates or local radiotherapy, skeletal immaturity)

Pathological fractures such as those observed in (but not limited to) Paget's disease or in metastatic bone diseases

Any active malignancy or patient undergoing treatment for a malignancy Study protocol: IndiALLO Version 4/19.03.2025 Page 9 von 32

Trial design

Treatments tested in this trial

  • Alveolar socket preservation with graft and flap surgery
  • allogenic bone block augmentation

Treatment groups

26 Participants
are divided into 2 treatment groups

Sponsors and collaborators